Table 5.
Suicidal behavior | Folate level | N patient | N (%) presence of suicidal behavior | Odds ratio (95% confidence interval) | |
---|---|---|---|---|---|
Unadjusted | Adjusteda | ||||
Present previous suicidal attempt | Normal range | 1,016 | 80 (7.9) | Ref | Ref |
Deficiency | 78 | 16 (20.5) | 3.02 (1.67–5.48)‡ | 2.32 (1.18–4.49)* | |
Higher baseline suicidal severity | Normal range | 1,016 | 322 (31.7) | Ref | Ref |
Deficiency | 78 | 40 (51.3) | 2.27 (1.43–3.61)‡ | 2.23 (1.34–3.69)† | |
Increased suicidal severity during follow-up | Normal range | 819 | 138 (16.8) | Ref | Ref |
Deficiency | 65 | 17 (26.2) | 1.75 (0.98–3.13) | 1.42 (0.77–2.64) | |
Fatal/non-fatal suicidal attempt during follow-up | Normal range | 819 | 29 (3.5) | Ref | Ref |
Deficiency | 65 | 9 (13.8) | 4.38 (1.98–9.70)‡ | 2.84 (1.19–6.77)* |
Baseline suicidal severity was defined using the brief psychiatric rating scale (BPRS) suicidality item scores, divided into lower [1 (not present) ~ 3 (mild)] and higher [4 (moderate) ~ 7 (extremely severe)]. Increased suicidal severity was defined as any instance in the increase in BPRS suicidality item score during 12-month pharmacotherapy.
Adjusted for age, sex, marital state, religious affiliation, monthly income, atypical feature, number of previous depressive episode, use vitamin supplement, and scores on Hospital Anxiety and Depression Scale-anxiety subscale and Alcohol Use Disorders Identification Test for baseline analyses, plus treatment steps over 12-month pharmacotherapy for follow-up analyses.
P < 0.05;
P < 0.01;
P < 0.001.